Holen Sie sich die Stockscreener-App
19.33
16.03%
-3.69
Handel nachbörslich:
19.19
-0.14
-0.72%
Schlusskurs vom Vortag:
$23.02
Offen:
$17.83
24-Stunden-Volumen:
143.87M
Relative Volume:
6.73
Marktkapitalisierung:
$4.40B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
28.01
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-26.89%
1M Leistung:
-39.00%
6M Leistung:
-62.78%
1J Leistung:
-54.57%
1-Tages-Spanne:
$16.35
$19.52
1-Wochen-Bereich:
$16.35
$27.77
52-Wochen-Spanne:
$16.35
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs ZTS, TAK, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
19.33 | 5.24B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
127.30 | 56.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.73 | 56.52B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
HLN
Haleon Plc Adr
|
10.88 | 48.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.47 | 39.90B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.12 | 20.90B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Stock Movers: Applovin, Oracle, Hims & Hers Health - bloomberg.com
Hims & Hers Stock Plunges 16%. Its Weight-Loss Drug Strategy Backfired. - Barron's
Stock Movers: Oracle, Kyndryl, Hims & Hers Health - bloomberg.com
Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More Movers - Barron's
Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1 - Law360
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? - The Motley Fool
Hims & Hers stock crashes after FDA announces plans to take 'decisive steps' against GLP-1 compounds - Yahoo Finance
Novo Nordisk Sues Hims & Hers Over Ozempic Copycats as the Weight-Loss Drug Wars Escalate - Gizmodo
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Key facts: Hims & Hers Health stock drops; DOJ probes weight-loss meds; lawsuit criticized - TradingView
Novo Nordisk Escalates Fight Against Hims & Hers - The Wall Street Journal
Hims & Hers Health: The Company Will Survive, But Investors Should Expect A 'Washout' - Seeking Alpha
FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast - Benzinga
Novo Nordisk says it’s suing Hims to halt obesity drug copycats - Ad Age
BofA Securities lowers Hims and Hers stock price target on Novo Nordisk lawsuit - Investing.com
Hims & Hers Shares Plunge as Novo Files Lawsuit Amid Telehealth Firm's Regulatory Scrutiny - marketscreener.com
Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War - Benzinga
Why Hims & Hers stock just got destroyed - MSN
Why Novo Nordisk Stock Just Popped - Yahoo Finance
Hims offered a $49 weight loss pill, then yanked it. Now Novo Nordisk is suing.Straight Arrow News - Straight Arrow News - SAN
HIMS Stock Plummets Over 23% to $17.68 - GuruFocus
These Stocks Are Today’s Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More - Barron's
Hims & Hers Health Faces Legal and Regulatory Challenges, Stock Plummets - GuruFocus
HIMS: Analyst TD Cowen Lowers Price Target, Maintains Hold Ratin - GuruFocus
Novo Says It’s Suing Hims to Halt Obesity Drug Copycats - bloomberg.com
HIMS’ 34% Pullback Reflects Rising Regulatory Risk - Trefis
Why Hims & Hers Health (HIMS) Stock Is Nosediving - Finviz
Why Hims & Hers Stock Just Got Destroyed - Yahoo Finance
HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment - Yahoo Finance
Novo says it’s suing Hims to halt obesity drug copycats - The Detroit News
HIMS Stock Rating Updated: Citigroup Lowers Price Target to $16. - GuruFocus
Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill - The Wall Street Journal
Stocks making the biggest moves midday: Oracle, Cleveland-Cliffs, Kyndryl, Nexstar, Workday, Hims & Hers - CNBC
Hims & Hers Faces New Risk as All GLP-1 Compounding Could be Restricted, BofA Says - marketscreener.com
The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash - FinancialContent
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn - Investopedia
Novo Nordisk sues Hims & Hers over alleged copycat drugs - Modern Healthcare News
HIMS Stock Experiences Significant Drop of 25.8% - GuruFocus
Novo sues Hims & Hers despite Wegovy pill offering U-turn - Yahoo Finance
Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron's
Hims & Hers (HIMS) Faces Regulatory Scrutiny Over Unapproved Dru - GuruFocus
Stocks to Watch Monday: Novo Nordisk, Hims & Hers, Apollo - The Wall Street Journal
FDA announces actions against telehealth compounding company Hims and Hers on the same day Novo Nordisk sues over Wegovy - Tri-State Alert
Novo Nordisk suing Hims & Hers over ‘copycat’ weight loss drug - Yahoo Finance
Novo Nordisk has lost most of its post-Wegovy market cap gains - Sherwood News
Stock Movers: Alphabet, Hims & Hers Health, Tegna - bloomberg.com
Kyndryl, Hims & Hers, Novo Nordisk, Valaris, Monday.com, Cleveland-Cliffs, and More Movers - Barron's
Biggest stock movers Monday: VAL, KD, HIMS, and more - Seeking Alpha
Hims & Hers Halts Semaglutide Pills Amid Regulatory Scrutiny - StocksToTrade
Gottlieb says Hims & Hers risks DOJ action over unapproved GLP-1 rival to Novo Nordisk- CNBC interview - Seeking Alpha
Hims & Hers Stock Plunges 25%. Its Weight Loss Drug Strategy Backfired. - Barron's
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):